Results 41 to 50 of about 288 (74)

Real-World Use of Letermovir and Maribavir for CMV Prophylaxis and Treatment in Solid Organ Transplant Recipients: Clinical Outcomes and Resistance Patterns From a Dual-Center Cohort. [PDF]

Pharmacotherapy
Xu MT, Wright A, Mah A, Matic N, Lowe C, Hong C, Belga S, Tsai WP.   +7 more
europepmc   +1 more source

A Novel Case of CMV Resistance to Valganciclovir and Maribavir in a Renal Transplant Patient. [PDF]

Transpl Int
Pearce H, Montgomery EK, Sheerin N, Ellam H.   +3 more
europepmc   +1 more source

[Maribavir effectively treated three patients with human herpesvirus-6B infection after allogeneic hematopoietic stem cell transplantation]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Jin CW, Li S, Wang LX, Huang JY, Hu XX, Zhang ZL.   +5 more
europepmc   +1 more source

Real-World Comparison of Maribavir to Foscarnet for the Treatment of Cytomegalovirus in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. [PDF]

Viruses
Ogawa L, Morinishi C, Multani A, Gaynor P, Beaird OE, Pham C, Schaenman JM.   +6 more
europepmc   +1 more source

Use of Maribavir for Multidrug Resistant Cytomegaloviremia in a Pediatric Oncology Patient. [PDF]

J Pediatr Hematol Oncol
Fisher JE, Mulieri K, Finch E, Ericson JE.   +3 more
europepmc   +1 more source

Evaluating Real-World Experience With Maribavir for Treatment of Refractory/Resistant Cytomegalovirus in Renal Transplant Recipients. [PDF]

Clin Transplant
Beechar VB, Phadke VK, Pouch SM, Mehta AK, Karadkhele G, Larsen CP, Woodworth MH.   +6 more
europepmc   +1 more source

Downfalls of Chemical Probes Acting at the Kinase ATP-Site: CK2 as a Case Study. [PDF]

Molecules, 2021
Atkinson EL, Iegre J, Brear PD, Zhabina EA, Hyvönen M, Spring DR.   +5 more
europepmc   +1 more source

Population Pharmacokinetics and Exposure-Response Relationships of Maribavir in Transplant Recipients With First Episode or Refractory Cytomegalovirus. [PDF]

CPT Pharmacometrics Syst Pharmacol
Sun K, Jomphe C, Gosselin NH, Pheng L, Durairaj C, Hang Y, Bhattacharya I.   +6 more
europepmc   +1 more source

Neuroprotective Effects of Hesperidin and CK2 Inhibitor DRB on Aβ_1-42-Induced Neurotoxicity in Differentiated SH-SY5Y Cells. [PDF]

Mol Neurobiol
Eciroglu-Sarban H, Altin-Celik P, Kelicen-Ugur P, Donmez-Altuntas H.   +3 more
europepmc   +1 more source

Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection. [PDF]

J Infect Dis
Chou S, Winston DJ, Avery RK, Cordonnier C, Duarte RF, Haider S, Maertens J, Peggs KS, Solano C, Young JH, Gu J, Pocock G, Papanicolaou GA.   +12 more
europepmc   +1 more source